Last reviewed · How we verify
HGP1405
At a glance
| Generic name | HGP1405 |
|---|---|
| Also known as | chlorthalidone |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics of HCP1401 and Co-administration of HCP0605, HGP1405 in Healthy Male Volunteers (PHASE1)
- Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HGP1405 CI brief — competitive landscape report
- HGP1405 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI